Respiratory syncytial virus (RSV) is a virus that leads to infections in the lungs and the respiratory tract. It commonly affects most children in the ages 2 or below. RSV can also infect adults. In adults and the older population, the symptoms of RSV are mild and similar to that of common cold. Infection with RSV can be severe in certain cases, particularly in premature infants and babies with underlying health conditions. RSV can also become serious in the older population or adults with heart and lung diseases, or any individual with a very weak immune system.

PART 01: Executive summary

Highlights

PART 02: Scope of the report

Market overview

Top-vendor offerings

PART 03: Market research methodology

Research methodology

Economic indicators

PART 04: Introduction

Key market highlights

PART 05: Disease overview

Understanding the disease

Symptoms

Causes

Risk factors

Complications

Tests and diagnosis

Key buying criteria

PART 06: Pipeline analysis

PART 07: Market landscape

Global respiratory syncytial virus drugs market

Five forces analysis

PART 08: Market segmentation by category of drug

Approved Drugs

Off-label drugs

PART 09: Geographical segmentation

Human respiratory syncytial virus drugs market in US

Human respiratory syncytial virus drugs market in

Europe

Human respiratory syncytial virus drugs market in

ROW

PART 10: Market drivers

Presence of large patient pool fuels market growth

Launch of novel products

Novel diagnostic tools increase patient population

PART 11: Impact of drivers

PART 12: Market challenges

Continuous change in guidelines from healthcare

organizations impacts market growth

Cyclical nature of market hinders growth opportunities

Limited drugs in market leading to low penetration

rates

PART 13: Impact of drivers and challenges

PART 14: Market trends

Emergence of new entrants likely to change market

dynamics

Growing strategic collaborations fostering innovation

Active participation from emerging economies toward

R&D

PART 15: Vendor landscape

Competitive scenario

PART 16: Key vendor analysis

AstraZeneca

AbbVie

GSK

Teva Pharmaceutical

Other prominent vendors

PART 17: Appendix

List of abbreviations

PART 18: Explore Technavio